ATE498016T1 - Transposon-system zur gezielten integration - Google Patents

Transposon-system zur gezielten integration

Info

Publication number
ATE498016T1
ATE498016T1 AT04709603T AT04709603T ATE498016T1 AT E498016 T1 ATE498016 T1 AT E498016T1 AT 04709603 T AT04709603 T AT 04709603T AT 04709603 T AT04709603 T AT 04709603T AT E498016 T1 ATE498016 T1 AT E498016T1
Authority
AT
Austria
Prior art keywords
poly
domain
transposase
peptide
targeted integration
Prior art date
Application number
AT04709603T
Other languages
English (en)
Inventor
Zoltan Ivics
Zsuzsanna Izsvak
Original Assignee
Max Delbrueck Centrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum filed Critical Max Delbrueck Centrum
Application granted granted Critical
Publication of ATE498016T1 publication Critical patent/ATE498016T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT04709603T 2003-02-10 2004-02-10 Transposon-system zur gezielten integration ATE498016T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03002637 2003-02-10
PCT/EP2004/001220 WO2004069994A2 (en) 2003-02-10 2004-02-10 Transposon-based targeting system

Publications (1)

Publication Number Publication Date
ATE498016T1 true ATE498016T1 (de) 2011-02-15

Family

ID=32842694

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04709603T ATE498016T1 (de) 2003-02-10 2004-02-10 Transposon-system zur gezielten integration

Country Status (7)

Country Link
US (1) US20080008687A1 (de)
EP (1) EP1594972B1 (de)
JP (1) JP2006518203A (de)
AT (1) ATE498016T1 (de)
DE (1) DE602004031325D1 (de)
DK (1) DK1594972T3 (de)
WO (1) WO2004069994A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2067402A1 (de) 2007-12-07 2009-06-10 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Transposon-vermittelte Mutagenese in Spermatogoniestammzellen
US8735156B2 (en) 2008-12-01 2014-05-27 The Board Of Regents Of The University Of Texas System Production and use of rat spermatogonial stem cell lines
US10689643B2 (en) * 2011-11-22 2020-06-23 Active Motif, Inc. Targeted transposition for use in epigenetic studies
EP2740353A1 (de) 2012-12-06 2014-06-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Neuartige induzierbare Tiermodelle für Stressverhalten
WO2014143383A1 (en) * 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CA3047313A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
US11913015B2 (en) 2017-04-17 2024-02-27 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
WO2019246486A2 (en) 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
JP2022502494A (ja) * 2018-09-25 2022-01-11 エモリー ユニバーシティー 細胞認識およびインテグレーションのための核酸
WO2020164702A1 (en) * 2019-02-13 2020-08-20 Probiogen Ag Transposase with enhanced insertion site selection properties
CN110776570A (zh) * 2019-10-22 2020-02-11 上海海洋大学 一种重组转座酶及其用途
CA3173696A1 (en) 2020-07-17 2022-01-20 Volker Sandig Hyperactive transposons and transposases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7097494A (en) * 1993-06-01 1994-12-20 Targeted Genetics Corporation Envelope fusion vectors for use in gene delivery
DK0973928T3 (da) * 1997-03-11 2010-08-09 Univ Minnesota DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
US5958775A (en) * 1997-07-25 1999-09-28 Thomas Jefferson University Composition and method for targeted integration into cells
WO2001030965A2 (en) * 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
IL154059A0 (en) * 2000-07-21 2003-07-31 Syngenta Participations Ag Zinc finger domain recognition code and uses thereof
AU2003268022B2 (en) * 2002-07-24 2009-02-05 Manoa Biosciences Inc. Transposon-based vectors and methods of nucleic acid integration

Also Published As

Publication number Publication date
EP1594972A2 (de) 2005-11-16
US20080008687A1 (en) 2008-01-10
DK1594972T3 (da) 2011-04-18
DE602004031325D1 (de) 2011-03-24
WO2004069994A3 (en) 2004-10-28
JP2006518203A (ja) 2006-08-10
WO2004069994A2 (en) 2004-08-19
EP1594972B1 (de) 2011-02-09

Similar Documents

Publication Publication Date Title
ATE536419T1 (de) Transposon basiertes targeting- system
ATE497540T1 (de) Transposon-system zur gezielten integration
DE602004031325D1 (de) Transposon-system zur gezielten integration
WO2007140505A3 (en) Vaccine carrier
SG162687A1 (en) Caustic stable chromatography ligands
ATE466868T1 (de) Zusammensetzungen und verfahren zur trennung von fusionsproteinen
NI200900097A (es) FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLÓGICA MEJORADA.
WO2007081851A3 (en) Affinity chromatography matrices and methods of making and using the same
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
NZ598770A (en) Monoclonal antibodies
WO2009081285A3 (en) Hepatitis c virus antibodies
WO2006127899A3 (en) (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
MX2018005512A (es) Agentes de union de esclerostina.
BRPI0411854A (pt) veìculos protéicos para vacinas
WO2007115571A8 (en) Erbb receptor-derived peptide fragments
ATE408624T1 (de) Verfahren zur reinigung von fsh
EA200600735A1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
DE602005026855D1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
WO2009025300A1 (ja) イミュノグロブリン結合能を有するペプチド
WO2010008159A3 (en) Mass- and property-tuned variable mass labeling reagents and analytical methods for simultaneous peptide sequencing and multiplexed protein quantification using thereof
WO2006132739A3 (en) Novel chemical compounds
WO2009108949A3 (en) Cold shock protein compositions and methods and kits for the use thereof
WO2007045019A3 (en) Polyoleosins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties